“We already have out offshore version and we’ve seen clear demand for a UCITS version of the fund,” Steer said. “It’s a very interesting time for looking at companies in Europe as it recovers, we see a lot of opportunities” he added. The two key elements of the strategy will be shorting overly expensive IPOs…
US drug giant tries again
With global equities a priority growth area, Schroders boosts its team with the appointment of Alex Tedder.
Investors across Europe have a different investment outlook compared to their counterparts in the UK according to a poll of more than 11,000 investors.
St James’s Place’s Chris Ralph explains why soft-closing funds is more than just a sensible thing to do but one of his firm’s ‘fiduciary responsibilities’.
Data show big year to year volatility
Mark Barnett says uncertainty over the strength of economic growth in emerging markets, particularly China, is not supportive for global growth.
Risks seen around bullish views on US economy, Fed
GlaxoSmithKline and AstraZeneca make big gains
Allianz Global Investors is considering merging Matthew Tilletts UK Unconstrained and UK Growth funds given the commonalities between the two portfolios, providing greater efficiency and better value for shareholders.
The recent sell-off in emerging markets looks overdone with the ASEAN nations and financials throwing up particularly attractive growth prospects, according to T. Rowe Price’s global equity manager Scott Berg.
Natixis Global Asset Management is said to be in late discussions with affiliate Harris Associates regarding a global concentrated equity fund for its UK product range.
